DEBIO-025 Cyclophilin Inhibitor Treatment of HCV Infection

作者：Campas C^*; Castaner R

来源：Drugs of the Future, 2008, 33(12): 1012-1017.

DOI：10.1358/dof.2008.33.12.1303612

• UNIL-025

Debio-025 (UNIL-025) is a first-in-class nonimmunosuppressive cyclophilin inhibitor that has demonstrated in vitro antiviral activity against hepatitis C virus (HCV) and HIV-1 superior to ciclosporin. Antiviral activity has been confirmed in vivo in animal models. Debio025 has been investigated in several clinical studies in healthy subjects and in patients infected with HCV, HIV or both. The drug was shown to be safe and well tolerated, although some adverse effects have been reported at daily doses of 2400 mg. Debio-025 has been found to reduce HCV viral load in infected patients in the clinical setting, either alone or in combination with interferon alfa. It has also demonstrated potential efficacy in HIV-infected subjects. Combined with the favorable pharmacokinetic and safety profile seen in initial clinical trials, Debio-025 appears to be a good candidate for the treatment of HCV infections, particularly in HIV-1/HCV-coinfected patients.

• 出版日期2008-12